Fig. 5: rhPRG4 enhances sorafenib and regorafenib effectiveness in inhibiting cell proliferation, preferentially in high CD44-expressing HCC cells. | Cell Death & Disease

Fig. 5: rhPRG4 enhances sorafenib and regorafenib effectiveness in inhibiting cell proliferation, preferentially in high CD44-expressing HCC cells.

From: Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

Fig. 5

Cells were analyzed by flow cytometry to quantify CD44 expression (histograms), and tested for growth rate for 72 hours in the presence or absence of sorafenib, regorafenib at a fixed concentration (2.5 µM), and increasing rhPRG4 concentrations (0–100 µg/ml). Drug effectiveness (% of drug-induced cell growth inhibition) is calculated for each rhPRG4 concentration as the percentage of cell growth inhibition induced by combined drug + PRG4 with reference to control (rhPRG4 alone). Data are expressed as the means ± SD of triplicates. T test (unpaired, two-tailed): *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page